Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool.
Schmieder V, Fieder J, Drerup R, Gutierrez EA, Guelch C, Stolzenberger J, Stumbaum M, Mueller VS, Higel F, Bergbauer M, Bornhoefft K, Wittner M, Gronemeyer P, Braig C, Huber M, Reisenauer-Schaupp A, Mueller MM, Schuette M, Puengel S, Lindner B, Schmidt M, Schulz P, Fischer S.
Schmieder V, et al.
J Biotechnol. 2022 Apr 10;349:53-64. doi: 10.1016/j.jbiotec.2022.03.010. Epub 2022 Mar 24.
J Biotechnol. 2022.
PMID: 35341894
Free article.